8-K/A: Taysha Gene Therapies Secures FDA Alignment for Pivotal Rett Syndrome Trial, Reports Strong Phase 1/2 Data for TSHA-102

Taysha Gene Therapies announced written FDA alignment on the pivotal Part B trial design for TSHA-102 in Rett syndrome, supported by positive clinical data from Part A of its REVEAL trials showing a 100% responder rate.

Summary

• Taysha Gene Therapies filed an 8-K/A to correct typographical errors in a corporate presentation (Exhibit 99.2) related to its TSHA-102 program.
• The company announced details of its planned pivotal Part B trial design for TSHA-102 in Rett syndrome, following written alignment from the U.S. Food and Drug Administration (FDA).
• Analysis of the International Rett Syndrome Foundation's (IRSF) natural history data established that patients six years of age or older are in a developmental plateau, with a near 0% likelihood of gaining or regaining developmental milestones.
• The FDA supports a single-arm, open-label pivotal trial (intend N=15) for TSHA-102, with patients serving as their own control and developmental milestone gain/regain as the primary endpoint in the developmental plateau population (>= 6 years).
• Positive clinical data from Part A of the REVEAL Phase 1/2 trials (N=10, 6-21 years) showed that 100% of patients gained or regained at least one developmental milestone post-TSHA-102 treatment.
• Improvements were observed across multiple outcome measures, with the high dose consistently outperforming the low dose, and dose-dependent effects deepening over time.
• TSHA-102 was generally well tolerated, with no treatment-related Serious Adverse Events (SAEs) or Dose Limiting Toxicities (DLTs) reported following low and high doses.
• The company expects to submit the pivotal Part B trial protocol and Statistical Analysis Plan (SAP) as an amendment to its Investigational New Drug (IND) application in the current quarter (Q2 2025).
• Pivotal trial initiation activities are anticipated in the third quarter of 2025.
• Taysha also notified agents of the suspension and termination of its At-The-Market (ATM) Prospectus, which allowed for the sale of up to $100,000,000 of common stock; no sales will occur under this mechanism until a new prospectus or registration statement is filed.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive clinical data for TSHA-102 in Rett syndrome, coupled with crucial FDA alignment on a pivotal trial design, which significantly de-risks the regulatory pathway. The 100% responder rate and dose-dependent improvements against a natural history baseline are highly compelling. The suspension of the ATM prospectus is a minor negative, and the Astellas option agreement introduces some future strategic considerations, but these do not overshadow the strong clinical and regulatory progress.

Positives

• Written FDA alignment on key elements of the pivotal Part B trial design for TSHA-102, including a single-arm, open-label trial with patients serving as their own control and developmental milestone gain/regain as the primary endpoint.
• 100% responder rate in REVEAL Part A (N=10) with all pediatric, adolescent, and adult patients gaining or regaining at least one defined developmental milestone post-TSHA-102.
• Observed dose-dependent effects, with the high dose cohort achieving a 100% responder rate 25% faster than the low dose cohort and showing accelerated functional benefits.
• TSHA-102 was generally well tolerated with no treatment-related Serious Adverse Events (SAEs) or Dose Limiting Toxicities (DLTs) reported.
• Statistically significant mean R-MBA score improvement compared to natural history data at both 6 and 12 months post-treatment.
• Early global improvement observed in Clinician Global Impression-Improvement (CGI-I) scores, with dose-dependent effects deepening over time.
• Natural history data analysis from the IRSF study (N=~1100) strongly supports the trial design by demonstrating a ~0% likelihood of developmental milestone gain/regain in untreated patients aged 6 years or older.
• TSHA-102 has received multiple expedited designations from regulatory bodies, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA.

Negatives

• The company suspended and terminated its ATM Prospectus for up to $100,000,000, which limits immediate capital raising flexibility through this specific mechanism.

Risks

• The reproducibility and durability of favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, are not guaranteed.
• There is a risk that TSHA-102 or other product candidates may not receive regulatory approval from the FDA or equivalent foreign regulatory agencies.
• The company is substantially dependent on TSHA-102, its sole product candidate in clinical development.
• Risks associated with the Option Agreement with Astellas, including potential disputes over whether the exercise of the Rett Option constitutes a change of control requiring stockholder approval, and the possibility of baseball arbitration for license terms if an agreement is not reached.
• Potential exposure to additional risks such as reputational harm and litigation if disputes arise with Astellas.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied.

Future Outlook

Taysha Gene Therapies plans to submit the pivotal Part B trial protocol and Statistical Analysis Plan (SAP) as an amendment to its IND application in the current quarter (Q2 2025) and anticipates initiating pivotal trial activities in the third quarter of 2025. The company's current cash resources are projected to support planned operating expenses and capital requirements into the fourth quarter of 2026.

Management Comments

• Sean P. Nolan, Chairman and CEO of Taysha, stated: "Our rigorous analysis of the robust natural history study dataset demonstrated that after six years of age, the likelihood of achieving defined developmental milestones across the core functional domains of Rett syndrome is highly improbable. Therefore, it is quite striking that we observed a 100% responder rate following treatment with TSHA-102, with all pediatric, adolescent and adult patients across varying disease severity gaining or regaining one or more developmental milestone... We believe this objective and clinically meaningful primary endpoint has the potential to redefine treatment expectations and expand the possibilities of gene therapy for patients with Rett syndrome."
• Dr. Jeffrey Neul, Rett Specialist, commented: "This innovative analysis and cumulative incidence models of the Rett syndrome natural history dataset help shape our understanding of the disease trajectory by establishing that the likelihood of gain and regain of developmental milestones is predictable after six years of age. Importantly, these data allow us to objectively measure how transformative therapies impact functional aspects of the disease that are essential to activities of daily living."
• Laura Hameed, CEO of the International Rett Syndrome Foundation (IRSF), added: "Their participation provided a deeper understanding of how Rett progresses over time, insights that are now helping shape meaningful clinical outcome measures and could someday lead to new treatments. Were pleased to support Tayshas efforts to build on this foundation and are hopeful about the progress it represents for families living with Rett syndrome."

Industry Context

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene, affecting an estimated 15,000 to 20,000 patients in the U.S., EU, and U.K. There are currently no approved disease-modifying therapies that address the genetic root cause of the disease. Taysha's TSHA-102 is an adeno-associated virus (AAV)-based gene therapy designed as a one-time treatment to deliver a functional MECP2 gene to the central nervous system. The market demand for Rett syndrome treatments is underscored by the commercial launch and uptake of other therapies like DAYBUE, although TSHA-102 aims to address the underlying genetic cause.

Comparison to Industry Standards

• The 100% responder rate observed in REVEAL Part A, where patients gained or regained developmental milestones, significantly exceeds the ~0% likelihood of such gains in untreated patients aged 6 years or older, as established by the robust IRSF natural history study data (N=~1100 females with up to 14 years follow-up).
• The statistically significant mean R-MBA score improvement demonstrated by TSHA-102 compared to natural history data provides objective evidence of functional benefit beyond the expected disease progression.
• The FDA's alignment on a single-arm, open-label pivotal trial design, with patients serving as their own control, is a strong validation of the observed clinical effects against the well-characterized natural history of Rett syndrome, indicating a high level of confidence in the potential for TSHA-102 to show a meaningful treatment effect.

Stakeholder Impact

• Shareholders: Highly positive news regarding clinical efficacy and regulatory progress for the lead program, TSHA-102, which could significantly increase shareholder value. The suspension of the ATM prospectus might introduce short-term uncertainty regarding immediate capital raising flexibility.
• Patients with Rett Syndrome and their Caregivers: The promising clinical data and clear path to a pivotal trial offer significant hope for a transformative, disease-modifying gene therapy that could dramatically improve functional outcomes and quality of life.
• Employees: Positive developments for the company's lead asset are likely to boost morale, ensure job security, and potentially lead to future growth opportunities.
• Regulatory Authorities (FDA): The written alignment on the pivotal trial design indicates a constructive and collaborative relationship, validating the company's approach and data.

Next Steps

• Submit pivotal Part B trial protocol and associated SAP as an amendment to the IND application in Q2 2025.
• Host three oral presentations related to TSHA-102 at the 2025 IRSF Rett Syndrome Scientific Meeting from June 9-11, 2025.
• Initiate pivotal Part B trial site activation and trial initiation activities in Q3 2025.
• Deliver the Rett Data Package to Astellas in mid-2025, which will trigger the 90-day Rett Option Period for Astellas to exercise its exclusive option.

Key Dates

Recommendation

Keywords

Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Clinical Trial, FDA Alignment, Pivotal Trial, REVEAL Trial, Natural History Data, Biotechnology, CNS Disorders, Rare Disease, Orphan Drug, AAV9